Novo’s subcutaneous Wegovy (semaglutide) has reduced body mass index (BMI) by at least 10% in 80% of children with obesity aged between six and 12, potentially opening the drug up for a label expansion in a younger population.
The Phase III STEP Young trial (NCT05726227), for which data were simultaneously presented at ObesityWeek 2026 and published in The New England Journal of Medicine, evaluated the safety and efficacy of investigational once-weekly semaglutide injection, with a maximum dose of 1.7mg or 2.4mg based on baseline body weight, in combination with a reduced-calorie diet and increased physical activity in children aged six to under 12 years with obesity.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
While Novo had already confirmed the trial met its primary endpoint in September, this is the first release of data.
At week 68, the estimated mean percentage reduction in BMI from baseline was 17.4% with Wegovy compared to a 2.2% increase with placebo. For the treatment regimen estimand, the estimated mean percentage reduction in BMI was 13.5% for Wegovy compared to a 2.7% increase with placebo.
Novo’s data also showed that at the end of the treatment period, if all children had adhered to treatment and did not use other weight-management interventions, 40.4% of those treated with Wegovy would no longer be classified as having obesity.
Dr Ania Jastreboff, professor of medicine for pediatric endocrinology at Yale School of Medicine, said: “Severe obesity can profoundly affect a child’s physical health, emotional well-being, and daily life. This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood. Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child’s trajectory back towards one of improving weight-related health.
The overall safety and tolerability profile of semaglutide observed in the STEP Young trial were consistent with previous Novo paediatric and adult trials of the drug, and no unexpected safety concerns were identified.
Childhood obesity is associated with several adverse health consequences, including type 2 diabetes, dyslipidaemia, hypertension, and obstructive sleep apnoea (OSA), and a modelling analysis published in The Journal of the American Medical Association (JAMA) suggested that young children with severe obesity whose obesity persists could experience a reduction in life expectancy of close to 50%.
If approved based on the data, this could be a significant advancement for paediatric obesity, as there are currently no US Food and Drug Administration (FDA) approved therapies for children with obesity who are aged under 12. Wegovy is approved for children aged 12 and older in the US, with Novo having gained this expansion for the drug in December 2022. Novo has not clarified the next steps for the drug.
While Lilly has not yet reached the same age group, the company did announce Phase III data at the same conference from the SURMOUNT-ADOLESCENTS programme (NCT06075667; NCT06439277). In the programme, its best-selling drug tirzepatide, which is marketed as Zepbound in the US for obesity, reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 years with obesity. At the end of the 72-week period, more than half of patients treated with the study drug no longer met the BMI criteria for obesity.
While Novo’s drug has shown clinical benefit in children, the World Health Organization (WHO) has urged health authorities to first seek lifestyle interventions to treat obesity in children and adolescents rather than opting for pharmacological treatment as a first port of call.
